drugset
drugset / Trial / NCT06987864

An Extension Clinical Study of BCD-148 for the Treatment of Patients With PNH Previously Treated in Clinical Study No. BCD-148-2/NOCTURN

NCT06987864 ↗

Phase 3 Completed 24 enrolled Biocad
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To study the long-term safety and efficacy of BCD-148 in patients with paroxysmal nocturnal hemoglobinuria (PNH), previously treated in clinical study (CS) BCD-148-2/NOCTURN

Timeline

Start
2020-04-13
Primary completion
2022-11-02
Completion
2022-11-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Eculizumab Monoclonal antibody — Intravenous

Indications

paroxysmal nocturnal hemoglobinuria